KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Change in Cash: 2017-2024

Historic Change in Cash for Aquestive Therapeutics (AQST) over the last 8 years, with Dec 2024 value amounting to $47.7 million.

  • Aquestive Therapeutics' Change in Cash rose 672.15% to $68.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $51.2 million, marking a year-over-year decrease of 3.41%. This contributed to the annual value of $47.7 million for FY2024, which is 1501.76% up from last year.
  • Latest data reveals that Aquestive Therapeutics reported Change in Cash of $47.7 million as of FY2024, which was up 1,501.76% from -$3.4 million recorded in FY2023.
  • Over the past 5 years, Aquestive Therapeutics' Change in Cash peaked at $47.7 million during FY2024, and registered a low of -$17.5 million during FY2020.
  • In the last 3 years, Aquestive Therapeutics' Change in Cash had a median value of -$751,000 in 2022 and averaged $14.5 million.
  • Per our database at Business Quant, Aquestive Therapeutics' Change in Cash slumped by 352.86% in 2023 and then skyrocketed by 1,501.76% in 2024.
  • Yearly analysis of 5 years shows Aquestive Therapeutics' Change in Cash stood at -$17.5 million in 2020, then surged by 78.41% to -$3.8 million in 2021, then soared by 80.15% to -$751,000 in 2022, then slumped by 352.86% to -$3.4 million in 2023, then spiked by 1,501.76% to $47.7 million in 2024.